At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Glembatumumab Vedotin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of GPNMB-Targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; NSC# 763737), in Recurrent or Refractory Osteosarcoma
In Brief
A Phase 2 clinical trial evaluating Glembatumumab Vedotin, Laboratory Biomarker Analysis, and 1 other intervention for Recurrent Osteosarcoma. Completed, enrolled 22 participants across 155 sites in 3 countries.
Detailed Summary
This phase II trial studies how well glembatumumab vedotin works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Monoclonal antibodies, such as glembatumumab vedotin, may find tumor cells and help kill them.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Osteosarcoma
CountriesCanada, Puerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartFeb 2016
Primary CompletionJun 2017
Study CompletionDec 2021
TodayJul 2026
First PostedJul 2, 2015
Enrollment StartFeb 16, 2016
Primary CompletionJun 30, 2017
Study CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11 years ago
Interventions
Glembatumumab Vedotindrug
Given IV
Laboratory Biomarker Analysisother
Correlative studies
Pharmacological Studyother
Correlative studies